Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sales were also boosted by demand for the anti-inflammatory drug Dupixent, a treatment for eczema, asthma and, more recently, chronic obstructive pulmonary disease, among other indications.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.

The drug is set to face competition from Merck's RSV drug this year. Meanwhile, Sanofi's asthma treatment, Dupixent, generated 3.46 billion euros in sales last quarter, but missed analysts ...